ClinicalTrials.gg
RecruitingNCT03642535Updated Mar 19, 2019

Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention

A Phase 4 interventional study of ALA in Actinic Keratoses, sponsored by Shanghai Dermatology Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-19.

Sponsored by Shanghai Dermatology Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Aug 2018; still recruiting 8 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing Aminolevulinic Acid in Keratosis, Actinic — 1 open to participants now, 2 under way, none of them phase 3. Aminolevulinic Acid · Keratosis, Actinic.

Planned enrollment
2nd of 29
300 · median 32
Started
2018
with 1 other
Phase 4
8 of 29
1 open now
Registered
24th of 29
by date

Among the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2018, is one of 8 in phase 4, and was the 24th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

1 of the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic is open now, in 1 country.

By country, each count listing its studies:

About Aminolevulinic Acid

Aminolevulinic Acid: first FDA approval 1999 (LEVULAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, or all of them as a file.
02

Study summary

Background Actinic keratoses (AKs) are often treated separately, lesion by lesion. However, in the past years, AKs have been described as a field disease and not limited to single clinically apparent lesions. Treatment should therefore target an area of field change which may treat the subclinical AKs and reduce the risk of development of further AKs, second tumours, and local recurrence.

Objectives The investigators sought to investigate whether field ALA-PDT of facial actinic keratosis would prevent new AKs, in comparison with a lesion area receiving the same ALA-PDT, in patients with clinical signs of field cancerization.

Methods Eighty patients, previously diagnosed as having AKs of the face, were randomized distribution into two groups. 10% aminolaevulinic acid (ALA)-PDT for field treatment was on one group and for a lesion area (Vehicle control cream was applied to the non-lesion area) was on the other group. During the next 5-year period of follow up, patients were clinically evaluated for new AKs.

03

Conditions studied

  • Actinic Keratoses

Browse trials for

Keywords

  • Photodynamic Therapy
  • Actinic Keratoses
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosed with AK (OLSEN classification grade I, II, III), aged > 18 years (Because no dosing or adverse event data are currently available on the use of topical aminolevulinic acid in patients \<18 years of age, children are excluded from this study);
  2. All patients are unfit and reluctant to undergo surgery for any reasons, and volunteered to participate in the study and ability to understand and the willingness to sign a written . Patents are willing to pay for the treatment, and agreed to take a picture of the skin lesions.

Exclusion criteria

Exclusion Criteria:

  1. Those who had ALA-PDT and any other studies that affect this study within 12 weeks ;
  2. There are other facial diseases that may affect the efficacy evaluation, such as other photodermatosis;
  3. Take phototoxic or photosensitizer within 8 weeks;
  4. Clinical and / or pathological prove that the tumor has invaded other organs or tissues;
  5. Serious persons;
  6. scar constitution;
  7. Patients are known to have skin photosensitivity, porphyria, or allergies to ALA, light or lidocaine;
  8. Persons are suffering from severe internal diseases, mental and mental illness, infectious diseases or pregnant or lactating women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    ALA for all face group

    Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Immediately afterwards, a 1-mm thick layer of 10% ALA was applied to the all face. The area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.

    Drug: ALA

  • Active comparator
    ALA for AK lesion group

    Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Then a 1-mm thick layer of 10% ALA was applied to the lesion and 5 mm of surrounding healthy tissue. Vehicle control cream was applied to the non-lesion area. All area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.

    Drug: ALA

Interventions

  • DrugAminolevulinic AcidStudies of Aminolevulinic AcidAminolevulinic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.

    Also known as: Aminolevulinic Acid

06

What researchers measure

Primary outcomes

  1. Number of new Actinic Keratoses

    The change in number of actinic keratoses at each follow-up will be measured as the primary outcome

    Time frame: 1, 3, 6, 9, 12, 18, 24, 30, 36 months after treatment

Secondary outcomes

  1. The clearance rate of Actinic Keratoses

    The change rate in lesion clearance of Actinic Keratoses at one month after treatment will be measured as the second outcome

    Time frame: 1 month after treatment

07

Study locations

1 of 1 sites recruiting
  • Shanghai Dermatology Hospital
    Shanghai, Jingan 200443, China
    Recruiting
    • Peiru Wang, PHD · Contactwpeiru@qq.com · 021-18017336579
    • Lude Zhu, MD · Contactzhulude0318@163.com · 021-15821804557
    • Xiuli Wang, PHD,MD · Principal investigator
    • Peiru Wang, PHD · Sub investigator
    • Hongwei Wang, PHD · Sub investigator
    • Kun Chen, PHD, MD · Sub investigator
    • Hang Li, PHD, MD · Sub investigator
    • Xiaojing Kang, PHD, MD · Sub investigator
08

References and documents

Publications

  • Pomerantz H, Hogan D, Eilers D, Swetter SM, Chen SC, Jacob SE, Warshaw EM, Stricklin G, Dellavalle RP, Sidhu-Malik N, Konnikov N, Werth VP, Keri J, Lew R, Weinstock MA; Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) Trial Group. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial. JAMA Dermatol. 2015 Sep;151(9):952-60. doi: 10.1001/jamadermatol.2015.0502. PubMed 25950503 ↗
  • Walker JL, Siegel JA, Sachar M, Pomerantz H, Chen SC, Swetter SM, Dellavalle RP, Stricklin GP, Qureshi AA, DiGiovanna JJ, Weinstock MA. 5-Fluorouracil for Actinic Keratosis Treatment and Chemoprevention: A Randomized Controlled Trial. J Invest Dermatol. 2017 Jun;137(6):1367-1370. doi: 10.1016/j.jid.2016.12.029. No abstract available. PubMed 28532759 ↗
  • Perl M, Goldenberg G. Field therapy in the treatment of actinic keratosis. Cutis. 2014 Apr;93(4):172-3. No abstract available. PubMed 24818175 ↗
  • Stockfleth E, Gupta G, Peris K, Aractingi S, Dakovic R, Alomar A. Reduction in lesions from Lmax: a new concept for assessing efficacy of field-directed therapy for actinic keratosis. Results with imiquimod 3.75%. Eur J Dermatol. 2014 Jan-Feb;24(1):23-7. doi: 10.1684/ejd.2014.2265. PubMed 24589500 ↗
  • Neittaanmaki-Perttu N, Gronroos M, Tani T, Polonen I, Ranki A, Saksela O, Snellman E. Detecting field cancerization using a hyperspectral imaging system. Lasers Surg Med. 2013 Sep;45(7):410-7. doi: 10.1002/lsm.22160. PubMed 24037822 ↗
  • Gupta G, Stockfleth E, Peris K, Aractingi S, Alomar A, Dakovic R, Dirschka T. Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis. J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1840-2. doi: 10.1111/jdv.12697. Epub 2014 Aug 29. PubMed 25174261 ↗
  • Pellacani G, Peris K, Guillen C, Clonier F, Larsson T, Venkata R, Puig S. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body. J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2192-8. doi: 10.1111/jdv.13211. Epub 2015 Aug 24. PubMed 26300464 ↗
  • Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, Hahn S, Lau K, Jager A, Schmitz B, Lubbert H, Szeimies RM. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz((R)) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED((R)) lamp. Br J Dermatol. 2016 Oct;175(4):696-705. doi: 10.1111/bjd.14498. Epub 2016 Jun 25. PubMed 26921093 ↗
  • Szeimies RM, Torezan L, Niwa A, Valente N, Unger P, Kohl E, Schreml S, Babilas P, Karrer S, Festa-Neto C. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol. 2012 Jul;167(1):150-9. doi: 10.1111/j.1365-2133.2012.10887.x. Epub 2012 Jun 1. PubMed 22329784 ↗
  • Eibenschutz L, Silipo V, De Simone P, Buccini PL, Ferrari A, Carbone A, Catricala C. A 9-month, randomized, assessor-blinded, parallel-group study to evaluate clinical effects of film-forming medical devices containing photolyase and sun filters in the treatment of field cancerization compared with sunscreen in patients after successful photodynamic therapy for actinic keratosis. Br J Dermatol. 2016 Dec;175(6):1391-1393. doi: 10.1111/bjd.14721. Epub 2016 Oct 18. No abstract available. PubMed 27167413 ↗

Individual participant data

Plan to share: Yes — underlie results

Supporting information: Clinical study report

Time frame: One year after finishing this study and for permanency

Access criteria: anyone who search pubmed

Data sharing details ↗ · www.ncbi.nlm.nih.gov

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2018 (actual). Primary completion is estimated for Jun 2025, 81 months after the start.

Of 19 phase 4 interventional studies under Keratosis, Actinic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's planned 81 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2018
First posted
Aug 22, 2018
StartActual
Aug 30, 2018
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Mar 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03642535
Lead sponsor
Shanghai Dermatology Hospital
Collaborators
Huadong Hospital, Peking University First Hospital, First Affiliated Hospital of Kunming Medical University, General Hospital of Ningxia Medical University, Chinese Academy of Medical Sciences
Responsible party
Xiuli Wang (Clinical Professor, Shanghai Dermatology Hospital) — Principal investigator
First posted
Aug 22, 2018
Start date
Aug 30, 2018
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Mar 19, 2019

Study contacts

Peiru Wang, PHD
Contact
wpeiru@qq.com
021-18017336579
Lude Zhu, MD
Contact
zhulude0318@163.com
021-15821804557
Xiuli Wang, PHD, MD
study chair · Shanghai Skin Disease Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion